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Abstract
Patients with diabetes are at higher risk of stroke and experience increased morbidity and mortality after stroke.
We hypothesized that cortical neurons develop insulin resistance, which decreases neuroprotection via circu-
lating insulin and insulin-like growth factor-I (IGF-I). Acute insulin treatment of primary embryonic cortical
neurons activated insulin signaling including phosphorylation of the insulin receptor, extracellular signal-
regulated kinase (ERK), Akt, p70S6K, and glycogen synthase kinase-3b (GSK-3b). To mimic insulin resistance,
cortical neurons were chronically treated with 25 mM glucose, 0.2 mM palmitic acid (PA), or 20 nM insulin before
acute exposure to 20 nM insulin. Cortical neurons pretreated with insulin, but not glucose or PA, exhibited
blunted phosphorylation of Akt, p70S6K, and GSK-3b with no change detected in ERK. Inhibition of the
phosphatidylinositol 3-kinase (PI3-K) pathway during insulin pretreatment restored acute insulin-mediated Akt
phosphorylation. Cortical neurons in adult BKS-db/db mice exhibited higher basal Akt phosphorylation than
BKS-db+ mice and did not respond to insulin. Our results indicate that prolonged hyperinsulinemia leads to
insulin resistance in cortical neurons. Decreased sensitivity to neuroprotective ligands may explain the increased
neuronal damage reported in both experimental models of diabetes and diabetic patients after ischemia-
reperfusion injury. Antioxid. Redox Signal. 14, 1829–1839.
Introduction
Stroke is the third leading cause of death in theUnited States behind heart disease and cancer (24). It is
clear from epidemiological studies that diabetes exacerbates
and/or is a principal cause of both stroke and myocardial
infarction (31, 43, 46). Ischemic stroke is a major macro-
vascular complication of diabetes and diabetic patients con-
sistently exhibit poorer outcomes and prognoses than
nondiabetic patients after a stroke (27, 31). Over the last 15 years,
our laboratory has extensively explored how peripheral sensory
neurons respond to hyperglycemia (16, 38, 62). Recently, we
began examining the effects of hyperglycemia on neurons of the
central nervous system. These studies arose because of our
growing interest in macrovascular disease and diabetes, with an
emphasis on stroke.
While neurons are not insulin dependent, they are insulin
responsive (5). Autoradiographic studies detect insulin re-
ceptors (InsR) in the brain of rodents and humans, and during
development, insulin facilitates glucose metabolism during
periods of neuronal growth (5). Increases in peripheral insulin
lead to parallel increases in the brain via InsR-mediated
uptake across the blood–brain barrier (12). The role of insulin
in the brain is not fully known, but insulin acutely alters
brain glucose utilization in a region-specific manner and al-
ters short-term memory (11). Moreover, insulin is a well-
documented growth factor for neurons of both the peripheral
and central nervous systems (66).
Insulin resistance is a state of decreased responsiveness of
target tissues to normal circulating levels of insulin and is a
major feature of type 2 diabetes, glucose intolerance, obesity,
dyslipidemia, and hypertension; that is, metabolic syndrome
(7). Recent epidemiological evidence suggests that the insulin
resistance associated with type 2 diabetes is a risk factor for
stroke (31, 46). Patients with diabetes show a two- to sixfold
increase in the risk of stroke compared to nondiabetic indi-
viduals. Population-based cohort studies demonstrate that
otherwise healthy individuals with metabolic syndrome
demonstrate a significant increase in stroke as well as car-
diovascular mortality (43). Insulin resistance also increases
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the risk of stroke recurrence and, cumulatively, a poorer
outcome and increased mortality (25). While these studies
clearly document the correlation of diabetes and stroke, the
underlying mechanism has yet to be identified.
Multiple factors, including hyperglycemic neuronal injury
and insulin resistance, may contribute to the reported increase
in mortality after stroke in diabetic patients. The contributions
of each component of the metabolic syndrome to stroke vary
and are controversial. Studies concerning the role of hyper-
glycemia on stroke demonstrate conflicting results; some con-
clude there is increased stroke risk with chronic hyperglycemia
(1, 37), whereas other work finds no such relationship (45). The
UK Prevention in Diabetes Study failed to demonstrate sig-
nificantly reduced risk of stroke in patients treated with tight
glucose control compared to conventional diet therapy (21).
Even though hyperlipidemia is a high risk factor for cardio-
vascular disease (CVD), its contribution to stroke is also un-
clear, with some studies reporting a beneficial effect of
cholesterol reduction, whereas others find no variation by lipid
profile among diabetic status (23, 36, 54). In contrast, studies
consistently demonstrate the relationship between hyper-
insulinemia and stroke, though less than the association with
CVD. The Atherosclerosis Risk in Communities Study reported
that hyperinsulinemia increased stroke risk by 1.19-fold/50 pM
increment in fasting insulin level (18). A 22-year follow-up
study of healthy Finnish men also demonstrated that hyper-
insulinemia carried a 2.1-fold increase in stroke risk after ad-
justment for age (48). Analysis of the data from the Third
National Health and Nutrition Survey demonstrates indepen-
dent association of insulin resistance with stroke (odds ratio
1.06) after adjustment with age, hypertension, myocardial in-
farction, claudication, physical activity, and HbA1C (6). Ulti-
mately, our understanding of the impact of individual elements
of the metabolic syndrome has the most impact on the in-
creased risk of stroke observed in diabetic patients requiring
more investigation at both the clinical and basic science levels.
Experimental studies of stroke and brain ischemia document
the contribution of neuronal apoptosis after stroke and brain
ischemia, and Akt signaling is a key regulator of these pro-
cesses (71). Akt, a serine/threonine kinase activated down-
stream of phosphatidylinositol 3-kinase (PI3-K), is a critical
signaling molecule in eukaryotic cells (71). Akt phosphoryla-
tion decreases immediately after global brain ischemia, fol-
lowed by a dramatic increase within 24 h before returning to
basal levels within 48 h (47). Preventing the initial decrease of
Akt phosphorylation by insulin-like growth factor-I (IGF-I)
treatment reduced neuronal death (30), whereas inhibition of
Akt and glycogen synthase kinase-3b (GSK-3b) by the PI3-K
inhibitor, LY294002, facilitated DNA fragmentation in hippo-
campal neurons (17). These results suggest that precise regu-
lation of Akt is critical for neuronal survival after brain injury.
The BKS.Cg-m+/+Leprdb/J mouse (BKS-db/db) is a spon-
taneous model of type 2 diabetes. Due to the expression of a
mutant leptin receptor, these mice are hyperphagic, which re-
sults in severe obesity hyperinsulinemia and insulin resistance
beginning at*4 weeks of age (http://jaxmice.jax.org/strain/
000642.htm). These animals exhibit increased serum lipids and
hyperglycemia similar to that seen in human patients and are
the most commonly used model of type 2 diabetes (58).
In the current study, we examined possible molecular
mechanisms regarding chronic insulin stimulation-mediated
blunting of Akt and its downstream effectors. We demon-
strate evidence of insulin resistance in an in vitro model of
hyperglycemia and cortical neurons from a mouse model of
type 2 diabetes. We conclude that chronic stimulation of Akt
may contribute to blunted insulin signaling in cortical neu-
rons and underlie, in part, the poor prognosis seen in diabetic
patients with stroke.
Materials and Methods
Antibodies and chemicals
All antibodies were purchased from Cell Signaling (Bev-
erly, MA) except Tau5 (Biosource International, Camarillo,
CA), anti-glyceraldehyde 3-phosphate dehydrogenase (anti-
GAPDH; Chemicon, Temecula, CA), and anti-actin (Santa
Cruz Biotechnology, Santa Cruz, CA). Inhibitors (LY294002
and U0126) were purchased from Calbiochem (La Jolla, CA).
PA was purchased from Nu-Chek Prep, Inc. (Elysian, MN).
All other chemicals were purchased from either Sigma (St.
Louis, MO) or Fisher Scientific (Fair Lawn, NJ).
Cortical neuron preparation
Cortical neurons were harvested from E15 embryos of
Sprague Dawley rats. The cortex was dissected and dissociated
using trypsin and plated in 12-well tissue culture plates coated
with poly-L-lysine (PLL). For immunohistochemistry (IHC),
cells were plated on glass coverslips coated with PLL in 24-well
culture plates. Cells were maintained in the feed medium
(Neurobasal medium; Invitrogen, Grand Island, NY) supple-
mented with 1·B27 without antioxidant (Invitrogen), antibi-
otics (penicillin, streptomycin, and neomycin; Sigma), 2.5lg/
ml albumin, 10lg/ml apo-transferrin, 0.1lg/ml biotin, 15lg/
ml D-galactose, 7 ng/ml progesterone, 16lg/ml putrescine,
4 ng/ml selenium, 3 ng/ml l-estradiol, 4 ng/ml hydrocorti-
sone, 3lg/ml catalase, and 2.5lg/ml superoxide dismutase.
Neurobasal medium contains 25 mM of glucose. The medium
was replaced with a fresh feed medium on days 1 and 3. On
day 6 (24 h before treatment), to exclude the effect of insulin
contained in B27, the culture medium was changed to treat-
ment medium (feed medium without B27). Insulin, glucose, or
palmitate was added on day 6 to the treatment medium for 24 h
treatment.
Mouse brain preparation
BKS-db/db and db + (BKS.Cg-m +/ + Leprdb/J, JAX Mice
stock No. 000642) were purchased from Jackson Laboratory
(Bar Harbor, ME). Mice were euthanized at 24 weeks of age
(20 week of diabetes). All mice were housed in a pathogen-free
environment, and cared for following the University of Mi-
chigan Committee on the Care and Use of Animals guidelines.
The mice were euthanized per our published protocols
with an overdose of sodium pentobarbital (38, 62). Brains
were cut in half and the cortex minced, and divided equally
into microcentrifuge tubes in the cortical neuron treatment
medium. The tubes were left at 37C for 45 min to stabilize
before stimulation with insulin or IGF-I.
Western immunoblotting
Cortical neuron cultures were lysed in RIPA buffer (Pierce,
Rockford, IL) containing protease inhibitor cocktail (Roche
Diagnostics, Indianapolis, IN). Mouse cortex was homoge-
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nized using a plastic pestle in a microcentrifuge tube in T-PER
tissue protein extraction reagent (Pierce) containing protease
inhibitor cocktail (Roche Diagnostics). Lysates were collected,
briefly sonicated, and centrifuged at 13,000 rpm for 15 min at
4C. Western immunoblotting was performed as described
previously (33). TBS with 0.01% Tween-20 and 5% fat-free
milk was used for blocking and antibody dilution. The incu-
bations with primary and secondary antibodies were carried
out either at RT for 2 h or at 4C overnight. The signal was
observed using enhanced chemiluminescence reagents (ECL;
Amersham Bioscience, Piscataway, NJ) or SuperSignal West
Femto Maximum Sensitivity Substrate (Pierce). Images were
captured using the Chemidoc XRS system and analyzed by
Quantity One software (Bio-Rad Laboratory, Hercules, CA)
(33) and the statistical analysis was performed by Prism
software (GraphPad, Inc., La Jolla, CA). All experiments were
repeated at least 3 times and representative results are pre-
sented in the figures. In some experiments, the nitrocellulose
membranes were incubated at 60C for 15 min in stripping
solution (2% SDS, 100 mM dithiothreitol and 100 mM Tris, pH
6.8) whereupon they were utilized for immunoblotting with
another antibody.
Immunohistochemistry
The cortical neurons cultured on PLL-coated coverslips
were permeabilized with phosphate-buffered saline (PBS)
containing 3% bovine serum albumin, 0.1% Triton X-100, and
1% normal goat serum (IHC buffer). The cells were incubated
with Tau5 antibody diluted in IHC buffer in a humidified
chamber at 4C overnight. After rinsing with PBS three times
for 5 min each, the cells were incubated with the anti-mouse
IgG secondary antibody conjugated with AlexaFluor 488
(Molecular Probes, Eugene, OR) for 2 h at RT. After rinsing
with PBS, the coverslips were mounted with the ProLong anti-
fade mounting medium containing DAPI (Molecular Probes).
The digital images were captured using a Spot-RT camera
(Diagnostic Instrument Inc., Sterling Heights, MI) attached to
Nikon Microphot-FXA microscope.
Statistical analysis
All experiments were repeated at least 3 times and pre-
sented as the mean– SEM. Statistical analysis was performed
by one-way analysis of variance with Tukey’s post analysis or
Student’s t-test using GraphPad Prism software (GraphPad
Software, Inc., San Diego, CA). Statistical significance was
defined as p< 0.05.
Results
Cortical neuron cultures were maintained for 3 and 6 days
in the standard feeding medium (see Materials and Methods
section). IHC for Tau5, a neuron-specific marker, confirmed
the cell’s neuronal phenotype (Fig. 1A). From day 3 to 6
in vitro, cortical neurons extended neurites and appeared
more mature (Fig. 1A). Treatment of the cortical neurons with
insulin or IGF-I after 6 days in vitro did not result in any
noticeable effects on cell size or neurite extensions (data not
shown). It is possible that the cells already have so many
neurites that we could not detect any measurable changes.
Both insulin and IGF-I influence the development of cortical
and hippocampal neurons by promoting neurogenesis, sur-
vival, and differentiation (3, 14, 52). Intracellular signaling
cascades that mediate the effect of insulin and IGF-I include
the mitogen-activated protein kinase (MAPK) and PI3-K/Akt
FIG. 1. Insulin and insulin-
like growth factor-I (IGF-I)
signaling in cultured cortical
neurons. (A) Cortical neurons
were harvested from E15 rat
embryos. The cells were cul-
tured for 3 or 6 days and
immunolabeled for tau, a
neuron-specific microtubule
associated protein (green,
detected by Tau5 antibody).
Nuclei were observed with
DAPI (blue). (B) Cortical
neurons cultured for 7 days
were stimulated with 20 nM
insulin or IGF-I for 0–2 h. Cell
lysates were prepared in
RIPA buffer and im-
munoblotted with the indi-
cated antibodies. These
experiments were repeated at
least 3 times and a represen-
tative result is shown. (To see
this illustration in color the
reader is referred to the web
version of this article at
www.liebertonline.com/ars).
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pathways (5). To examine insulin and IGF-I signaling in our
system, cortical neurons were treated with 20 nM insulin or
IGF-I for 0–2 h followed by Western immunoblotting. Insulin
stimulation induced a time-dependent increase in the phos-
phorylation (i.e., activation) of intracellular signaling mole-
cules, including InsR, and its downstream targets, Akt, GSK-
3b, and p70S6K (Fig. 1B). Phosphorylation of extracellular
signal-regulated kinase (ERK) was not prominent and, in
many cases, not different from the control (untreated neu-
rons). Each blot was stripped and reprobed with antibodies
against total protein as well as GAPDH to confirm equal
protein loading. IGF-I treatment also resulted in a similar re-
sponse; however, activation of Akt and p70S6K was generally
stronger compared to insulin stimulation.
Hyperglycemia, dyslipidemia, and hyperinsulinemia are
characteristic of type 2 diabetes and the metabolic syndrome,
all of which may contribute to insulin resistance (7). We next
examined the contribution of each of these factors to insulin
resistance in cortical neurons. To create an in vitromodel of the
metabolic syndrome and assess insulin resistance, cortical
neurons were treated with 25 mM added glucose, 0.2 mM PA,
or 20 nM insulin for 24 h. The medium was then replaced with
a fresh treatment medium for 30 min and the cells were ex-
posed to 20 nM insulin for 15 min. Twenty-four hour insulin
treatment resulted in reduced InsR phosphorylation, whereas
24 h glucose and PA treatment resulted in an increase in InsR
phosphorylation (Fig. 2A). In untreated cortical neurons, Akt
is activated after 15 min of insulin treatment. Twenty-four
hour insulin treatment reduced this response to subsequent
short-term insulin treatment. In contrast, 24 h of glucose or PA
had no effect on the activation of Akt in response to short-term
insulin treatment. An increase in basal Akt phosphorylation
was noted after 24 h insulin treatment (Fig. 2A). Densitometric
analysis confirmed that only insulin pretreatment resulted in
a statistically significant decrease in insulin-stimulated Akt
phosphorylation (Fig. 2B).
Full activation of Akt requires sequential phosphorylation
of Thr308 and Ser473 by PDK1 and mammalian target of ra-
pamycin complex 2 (mTORC2), respectively (71). The 24 h
insulin treatment decreased the phosphorylation at both of
these sites (Fig. 3A). Densitometric analysis demonstrates a
statistically significant suppression of Akt phosphorylation
after 24 h insulin pretreatment (Fig. 3B). p70S6K and GSK-3b
are two important signaling molecules mediating Akt’s role in
survival, neuronal differentiation, and metabolism (71). In
parallel with the effect on Akt phosphorylation, 24 h insulin
treatment also reduced short-term insulin-stimulated p70S6K
and GSK-3b phosphorylation (i.e., activation of p70S6K and
inactivation of GSK-3b). When p70S6K is phosphorylated, it
displays slower migration (34). We observed a slower mi-
grating band of p70S6K in insulin-stimulated samples with-
out pretreatment but not in samples pretreated with insulin
for 24 h (Fig. 3A). Total protein levels of p70S6K and GSK-3b
were not affected (Fig. 3A). In contrast, IGF-I-stimulated Akt
phosphorylation was less affected by insulin pretreatment
even up to 48 h without a reduction in total Akt protein (Fig.
3C). Of the three treatments tested, these results suggest that
hyperinsulinemia, rather than hyperglycemia or hyperlipid-
emia, is the main factor responsible for the development of
insulin resistance in cortical neurons.
We next explored the possible mechanism behind the re-
duction in Akt activation after chronic insulin treatment.
During 24 h insulin treatment, cortical neuron cultures were
incubated without or with inhibitors of Akt (LY294002) or
ERK (U0126) signaling pathways. After 24 h the cells were
washed with HBSS and incubated in a fresh treatment me-
dium (without insulin or inhibitors) for 30 min. The cultures
were then treated with 20 nM insulin for 15 min. As in the
previous experiments, cortical neurons chronically pretreated
with insulin followed by acute insulin treatment exhibited
reduced Akt phosphorylation (Fig. 4A). Combined treatment
with insulin and the PI3-K inhibitor, LY294002, restored Akt
phosphorylation by acute insulin treatment to control levels.
The MAPKK inhibitor, U0126, had no effect on Akt phos-
phorylation. Densitometric analysis (Fig. 4B) confirms that
LY294002 treatment (lane 5) restored Akt phosphorylation,
which was significantly higher than without inhibitor (lane 4)
or U0126 (lane 6) treatment and displayed no statistically
significant difference compared to untreated neurons (lane 2).
As in the previous experiments, ERK phosphorylation was
not significantly affected by 24 h insulin treatment or by either
inhibitor. These results suggest that chronic hyperactivation
of Akt by insulin prevents further activation by acute insulin
FIG. 2. Chronic insulin stimulation mimicking hyper-
insulinemia downregulates the ability of cortical neurons to
respond to acute insulin stimulation. (A) Cortical neurons
were incubated with 25 mM glucose (Glu), 0.2 mM palmitic
acid (PA), or 20 nM insulin (Ins) for 24 h and then stimulated
with 20 nM insulin for 15 min. (B) Densitometric analysis of
Akt phosphorylation. Cell lysates were prepared in RIPA
buffer and immunoblotted with antibodies against phos-
phorylated insulin receptor (pInsR) or Akt (pAkt). The blots
were stripped and reprobed with antibodies against total InsR
or Akt. Anti-actin immunoblot demonstrate the equal loading
of the proteins. *p< 0.05 compared to insulin-stimulated
control cells using one-way analysis of variance (ANOVA).
Akt phosphorylation in Glu and PA pretreated cells were not
statistically significant compared to control cells.
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treatment. Insulin treatment-induced InsR phosphorylation
was not affected by the chronic insulin, LY294002, or U0126
treatments (Fig. 5). The phosphorylation pattern of p70S6K
and GSK-3b paralleled that of Akt phosphorylation (Fig. 5).
p70S6K displayed decreased mobility when phosphorylated
(lanes 2 and 5) (34). These results confirm the upstream
requirement of Akt for the activation of these signaling
molecules.
These observations were confirmed in an animal model of
type 2 diabetes, the BKS-db/db mouse. The BKS.Cg-m+/+
Leprdb/J, commonly known as BKS-db/db, expresses a ho-
mozygous mutation of the leptin receptor and demonstrates
typical characteristics of type 2 diabetes, including obesity,
hyperinsulinemia, and hyperglycemia (http://jaxmice.jax
.org/strain/000642.html). BKS-db + mice are heterozygous
for this mutation and serve as a control. At 24 weeks of age (20
weeks of diabetes), cortex was harvested from BKS-db/db
and db+ and treated with 20 nM insulin for 0–15 min. Insulin
stimulation resulted in a time-dependent increase in Akt
phosphorylation in BKS-db + cortex (Fig. 6A). In contrast, db/
db cortex displayed higher basal Akt phosphorylation, and
insulin treatment did not increase this phosphorylation.
Densitometric analysis demonstrates statistically significant
increases in Akt phosphorylation in BKS-db + cortex but no
such changes from db/db cortex (Fig. 6B). These results
confirm our in vitro observations and demonstrate that hy-
perinsulinemia may induce insulin resistance in vivo by the
same mechanism, that is, reduced Akt activation.
Discussion
Hyperinsulinemia resulting from systemic insulin resis-
tance is characteristic of type 2 diabetes and is also part of the
constellation of symptoms associated with the metabolic
syndrome (7). Because insulin crosses the blood–brain barrier,
its levels are also increased within the central nervous system
(15, 57). We hypothesized that increased insulin signaling
would result in insulin resistance within the central nervous
system, contributing to the increased neuronal damage seen
in patients with type 2 diabetes after ischemia-reperfusion
injury. In neurons, the PI-3K/Akt pathway is normally acti-
vated by insulin and IGF-I and is critical for translating the
protective effects of these ligands (14, 52). In the current study,
we found that long-term (24 h) exposure to insulin increased
Akt activation and severely blunted this response after sub-
sequent short-term insulin treatment. Acute Akt signaling
was restored when the PI3-K inhibitor, LY294002, was added
with 24 h insulin, indicating that hyperstimulation of this
pathway is involved in insulin resistance. These observations
were confirmed in an animal model of type 2 diabetes, the
BKS-db/db mouse. Cortical neurons harvested from these
animals exhibited the same blunted Akt activation after a
15 min exposure to insulin as observed under chronic insulin
stimulation in vitro.
Cortical neurons in vitro extend neurites and express neu-
ronal markers, including tau. These neurons also express both
insulin and IGF-I receptors and respond to physiologic levels
FIG. 3. Chronic insulin treatment reduces insulin stimulated Akt phosphorylation and downstream signaling mole-
cules. (A) The cells were treated without or with 20 nM insulin for 24 h and stimulated with 20 nM insulin for 15 min. (B)
Densitometric analysis of Akt phosphorylation (Ser473). Statistical significance was confirmed by Student’s t-test. (C) The
cells were pretreated with insulin for 24 or 48 h and then stimulated with 20 nM IGF-I for 0, 15, or 60 min. Cell lysates were
prepared in RIPA buffer and immunoblotted with the indicated antibodies.
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of these ligands as demonstrated by activation of Akt and
ERK1/2 and downstream targets of Akt, GSK-3b, and
p70S6K. These downstream effectors are activated within
15 min of treatment. Insulin signaling was followed for 2 h at
which time both the total levels of InsR and its activated form
are diminished. This may be due to InsR recycling (10) or to
saturation of intracellular substrates.
Once a normal signaling pattern was established, we ex-
amined the impact of long term insulin exposure on insulin
signaling. Epidemiological data reveal that diabetic patients
have an increased risk for stroke and poorer outcomes after
stroke including increased infarct size and increased hemor-
rhage after initial ischemia (31, 43, 46). Many of these studies
cite insulin resistance as the major risk factor; therefore, we
examined cortical neuron cultures after chronic insulin treat-
ment as a model of neuronal insulin resistance. As discussed
above, cortical neurons respond to insulin and IGF-I stimula-
tion with activation of Akt within 15 min. To examine the fac-
tors associated with insulin resistance, cortical neurons were
treated with insulin, glucose, or PA to mimic hyperinsulinemia,
hyperglycemia, and hyperlipidemia, respectively.
There are few direct reports regarding insulin resistance in
neurons of the central nervous system; however, several
studies document increased neuronal damage when insulin
signaling is blocked. Neuron-specific InsR knock-out mice
exhibit decreased Akt and GSK-3b activation and increased
tau phosphorylation, but with no memory dysfunction or
neuronal loss (53). In contrast, diet-induced insulin resistant
mice exhibited similar decreases in Akt signaling coupled
with increased amyloid plaques and decreased spatial per-
formance (26). Both the BKS-db/db and ob/ob mice are in-
sulin resistant and sustain greater infarct areas and increased
behavioral deficits than their nondiabetic littermates (60).
Although these studies did not specifically address insulin
signaling, they confirm data collected from human patients
regarding the negative impact of diabetes on ischemia-
reperfusion injury.
Neurons preferentially use glucose as their main energy
source. The neurobasal (NB + ) medium contains 25 mM,
which is optimal for maintaining neuronal health and axonal
outgrowth (51). In our previous work examining the effects of
diabetes on peripheral sensory neurons, we demonstrated
that 20–25 mM (total 50 mM, 280 mg/dl) added glucose in-
duces oxidative stress, mitochondrial depolarization, and
programmed cell death (38, 62). These levels are within the
range of that detected 2 h postprandial (200 mg/dl, 11.1 mM)
in a patient with poorly regulated diabetes (42). With regard
to the central nervous system, brain glucose levels are two- to
threefold lower than the plasma glucose levels. Silver and
Erecinska (57) demonstrated that brain glucose levels are 3-
fold lower both under control (2.4 mM brain vs. 7.6 mM blood)
and hyperglycemic (4.5 mM brain vs. 15.2 mM blood) condi-
tions. Most importantly, however, brain glucose levels exhibit
a linear correlation with peripheral blood glucose levels (15,
57); that is, an increase in peripheral blood glucose directly
increases brain glucose. Although it is almost impossible to
create primary culture conditions that exactly replicate in vivo
conditions, we believe that our in vitro experiments accurately
reflect diabetic conditions within the central nervous system
as long as we maintain the ratio of glucose increase. Our
findings demonstrate that hyperglycemia had no significant
effect on insulin signaling.
To examine the effects of hyperlipidemia, cortical neurons
were treated with PA for 24 h. Our recent results in peripheral
FIG. 4. LY294002 pretreatment prevents hyperinsulinemia induced downregulation of Akt stimulation. (A) Cortical
neurons were incubated with insulin along with 20 lM LY294002 (LY) or U0126 (U) for 24 h. The cells were washed and
incubated in a fresh treatment medium for 30 min before acute insulin stimulation for 15 min. Immunoblotting was per-
formed using the antibodies against phosphorylated Akt or extracellular signal-regulated kinase (ERK) and then stripped and
reprobed for total protein as well as for actin. (B) Densitometric analysis of Akt phosphorylation. *p < 0.05 by one-way
ANOVA compared to other treatment groups.
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sensory neurons suggest that dyslipidemia contributes to di-
abetic neuropathy by increasing plasma-oxidized low-density
lipoprotein, which directly leads to oxidative stress and injury
in dorsal root ganglion neurons via LOX-1 (61). In the current
study, exposure to PA had no effect on insulin signaling.
Excessive exposure to insulin, rather than hyperglycemia,
has been suggested as the primary instigator of insulin resis-
tance in a type 1 diabetes mouse model (40). Of these pa-
rameters tested in the current study (high glucose, PA, or
insulin), only chronic insulin treatment prevented activation
of Akt. Specifically, phosphorylation of Akt at Thr308 and Ser
473 was blocked. In addition to reduced Akt activation, the
phosphorylation of downstream effectors, GSK-3b and
p70S6K, were diminished after chronic insulin treatment. This
observation is specific for insulin signaling, as acute IGF-I
activation of Akt was not affected by chronic insulin
treatment.
Based on our in vitro findings and the reports outlined
above in diabetic mice, neuronal insulin resistance was ex-
amined in the BKS-db/db mouse. These mice are obese, be-
come hyperinsulinemic at 10–14 days of age and similar to
human diabetic patients, experience more damage after is-
chemia-reperfusion injury to the brain (60). Because of their
extreme insulin resistance, it is very difficult to separate the
effects of hyperglycemia from chronic insulin exposure in
these animal models. Our observation that neurons dissected
from BKS-db/db mice at 24 weeks of age (20 week of diabetes)
are unable to phosphorylate Akt in response to acute insulin
treatment argues for hyperinsulinemia. Further examina-
tion of these animals or other type 2 models of diabetes is
warranted.
The absence of leptin signaling in the db/db mouse is re-
sponsible for hyperphagy; the dramatic obesity that follows
nonstop eating results in insulin resistance and diabetes in this
model. Type 2 diabetes may also be induced by feeding mice a
Western style high-fat diet (65). While our data clearly sup-
port a role for insulin resistance in decreased Akt signaling,
leptin also decreases Akt activation in the rat brain (8). In our
studies, the lack of leptin receptor should minimize the effects
of leptin signaling in this regard. Leptin receptors are ex-
pressed in the hypothalamus, cerebellum, and cerebral cortex
(8) and are neuroprotective after ischemic injury (69). Further
studies of diet-induced type 2 models with intact leptin sig-
naling are an important step toward examining the combined
role of insulin resistance and leptin signaling with regard to
neuronal survival after ischemia-reperfusion injuries.
The beneficial effects of insulin treatment after ischemic
injury have been demonstrated in in vitro and in vivo models,
and in all cases reported depend on Akt activation. In vitro
induction of oxidative stress decreases constitutive tyrosine
phosphorylation of the insulin and IGF-I receptors and would
normally result in neuronal apoptosis. Insulin treatment re-
stores baseline activation of these receptors and increases
activation of Akt and subsequent maintenance of Bcl-2 and
inhibition of caspase 3 (14). In vivo, a single bolus of insulin
given at the onset of re-perfusion activated Akt, protected
hippocampal neurons from apoptosis, and spared learning
and memory (52). Akt also plays a key role in neuroprotection
FIG. 5. Chronic insulin treatment downregulates p70S6K
and glycogen synthase kinase-3b (GSK-3b) phosphoryla-
tion, which is reversed by phosphatidylinositol 3-kinase
(PI3-K) inhibitor pretreatment. Cortical neurons were in-
cubated with insulin along with 20 lM LY294002 (LY) or
U0126 (U) for 24 h. The cells were washed and incubated in a
fresh treatment medium for 30 min before acute insulin
stimulation for 15 min. Immunoblotting was performed us-
ing the antibodies against phosphorylated InsR, p70S6K, or
GSK-3b and then stripped and reprobed for total protein as
well as for glyceraldehyde 3-phosphate dehydrogenase
(GAPDH).
FIG. 6. Insulin cannot stimulate Akt phosphorylation in
db/db cortex. (A) Cortical slices were harvested from BKS-
db+ and db/db mice and stimulated with 20 nM insulin as
described in the Materials and Methods section. Typical re-
sults from two out of five animals tested from each group are
shown. (B) Densitometry analysis of Akt phosphorylation.
*p< 0.05 by one-way ANOVA compared to nonstimulated
db+ cortex.
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by baicalein (39), simvastatin (9), and humanin (67), which are
all implicated in neuronal survival after ischemic injury.
Therefore, suppression of Akt phosphorylation (i.e., activa-
tion) due to insulin resistance can profoundly affect neuronal
survival after ischemic injury and stroke. The specificity of the
PI-3K/Akt pathway in the induction of insulin resistance in
cortical neurons is underscored by blocking this pathway
with LY294002. When cortical neurons were exposed to in-
sulin and LY294002, Akt activation was prevented and acute
insulin signaling activated the expected range of downstream
proteins. Similar results are reported in mice fed with a high-
fat diet. These mice develop insulin resistance with increased
basal Akt phosphorylation and display increased oxidative
stress (41). When the mice were treated with LY294002 during
the day time (when mice usually do not eat), all these changes
were reversed with increased insulin sensitivity. Therefore,
Akt may be the key factor connecting increased risk of is-
chemia and stroke as well as poor prognosis after stroke in
patients with diabetes and other metabolic syndromes. Sev-
eral signaling molecules regulated by Akt, including Bad,
forkhead transcription factor (FKHR), and GSK-3b, are im-
plicated in ischemia/reperfusion-mediated neuronal injury
(71) and are discussed below.
Bad is a proapoptotic member of the Bcl family of proteins
(13). After cerebral ischemia, Bad translocates to the outer
membrane of the mitochondria and dimerizes with Bcl-xL (2).
This process triggers cytochrome c release and caspase acti-
vation. Akt-induced phosphorylation inactivates Bad and
prevents cell death (13). Peroxisome proliferator-activated
receptor (PPAR)-c is a ligand-modulated transcription factor
activated by insulin-sensitizing thiazolidinediones and a
therapeutic target for treating type 2 diabetes (22). Rosiglita-
zone, troglitazone, and pioglitazone have all demonstrated
protective effects against ischemia-reperfusion–induced
myocardial damage and cerebral infarction in animal studies
(55, 59, 68). These effects were mediated by preventing is-
chemia-induced degradation of Akt, Bcl-2, and Bcl-xL and
subsequent phosphorylation and inactivation of Bad (19).
In response to apoptotic stimuli (including ischemia) FKHR
translocates to the nucleus and initiates the expression of
proapototic proteins such as FAS. Akt phosphorylates FKHR,
leading to suppression of its apoptotic activity and promoting
cell survival (50). The vanadyl compound bis(1-oxy-2-
pyridinethiolato)oxovanadium(IV) [VO(OPT)] is neuropro-
tective in a mouse ischemic model via Akt activation and
subsequent phosphorylation of FKHR (56).
Active (i.e., dephosphorylated) GSK-3b is increased after
ischemic injury and GSK-3b inhibitor reduces ischemic in-
farction (35). Akt phosphorylates and thus inactivates GSK-3b
(63). Lithium, traditionally used as a mood stabilizer, displays
neuroprotective effects after stroke by increased expression of
brain-derived neurotrophic factor and Bcl-2 and inhibition of
GSK-3b (64). Induction of focal ischemic stroke by middle
cerebral artery occlusion in diabetic mice exacerbated ische-
mia-induced cognitive deficits and brain infarction (70). These
changes were accompanied with increased tau phosphoryla-
tion and decreased GSK-3b phosphorylation.
Even though less studied, p70S6K is also involved in pre-
venting neuronal cell death after ischemic brain injury.
Phosphorylation of p70S6K was decreased during transient
focal ischemia (29) and the protective effect of thrombin
against focal cerebral ischemia was accompanied with in-
creased phosphorylation of p70S6K (28). Our current report
demonstrates the regulation of GSK-3b and p70S6K phos-
phorylation by Akt in cortical neurons. Impairment of Akt
activity by hyperinsulinemia-induced insulin resistance af-
fects the downstream signaling molecules involved in ische-
mic/stroke injury and increases neuronal cell death. We are
currently investigating the signaling downstream of Akt in
both cortical neurons in vitro and in the BKS-db/db mice. Our
hypothesis is summarized in Figure 7.
In summary, our experiments reveal that chronic insulin
stimulation in vitro and in vivo results in a decrease in acute
insulin-stimulated Akt activation, a form of insulin resistance
in cortical neurons. Insulin resistance (or metabolic syn-
drome) is a risk factor for stroke (31) and its recurrence (25).
Six out of nine recent epidemiological studies provide evi-
dence that insulin resistance is associated with stroke (31).
Insulin resistance was observed in up to 50% of the patients
with transient ischemic attack or stroke (32). The prevalence of
metabolic syndrome was almost twice as high (43.5% vs.
22.8%) in people with a self-reported history of stroke
FIG. 7. Model for increased neuro-
nal injury due to insulin resistance
during metabolic syndrome includ-
ing type 2 diabetes. Ischemic insult
induces cell death through proa-
poptotic signaling molecules, includ-
ing forkhead transcription factor
(FKHR), GSK-3b, and Bad, which can
be prevented by Akt activation. Insulin
resistance state induced by hyper-
insulinemia prevents Akt activation
and inhibits cell survival.
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compared to those without a history of vascular disease (46).
Individuals with metabolic syndrome, even without diabetes
or CVD, are at increased risk of long-term cardiovascular
outcomes, suggesting the importance of identifying metabolic
syndrome early to intervene in the possible development of
CVD and stroke (43). Precise regulation of Akt phosphoryla-
tion is critical for neuronal survival during brain ischemia (20,
47, 71). Our results suggest for the first time that decreased
responsiveness of Akt phosphorylation due to hyper-
insulinemia may explain the increased neuronal damage re-
ported in both experimental models of diabetes and diabetic
patients (4, 44, 49). Experiments are ongoing to determine the
role(s) of InsR turnover and the signaling capacity of intra-
cellular substrates responsible for insulin signal transduction.
The inability of neurons to respond to circulating growth
factors, including insulin or IGF-I, provides a potential ex-
planation for the increased neuronal damage observed in di-
abetic human patients after stroke.
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